Clinical trial
TMC207-TIDP59-C211: A Phase 2, Open-label, Multicenter, Single-arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Anti-mycobacterial Activity of TMC207 in Combination With a Background Regimen (BR) of Multidrug Resistant Tuberculosis (MD
NCT02354014 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- TMC207-TIDP59-C211: A Phase 2, Open-label, Multicenter, Single-arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Anti-mycobacterial Activity of TMC207 in Combination With a Background Regimen (BR) of Multidrug Resistant Tuberculosis (MD
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 2
- Overall status
- Suspended
- Start date
- May 3, 2016
- Completion date
- November 2, 2028
- Enrollment
- 60 (estimated)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.